Cleveland Clinic Health System - East Region
Cleveland Clinic Health System - East Region was paid $32.76M by Medicaid between Jan 2018 and Dec 2024, across 427 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
MAYFIELD HTS, OH 44124
Next to other General Acute Care Hospital providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,684 | $876K | |
| 2019 | 23,374 | $1.06M | |
| 2020 | 15,668 | $975K | |
| 2021 | 34,797 | $1.94M | |
| 2022 | 53,970 | $2.92M | |
| 2023 | 349,691 | $15.00M | |
| 2024incomplete | 273,008 | $9.99M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 27,925 | 25,678 | $3.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 26,587 | 22,406 | $3.48M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 34,180 | 28,351 | $3.45M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.7% | 9,309 | 6,050 | $3.18M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 6.3% | 14,002 | 12,408 | $2.06M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 15,619 | 13,572 | $1.92M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 3,913 | 3,216 | $987K |
| G0378 | Hospital observation service, per hour | 2.3% | 10,255 | 4,406 | $769K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 3,128 | 2,583 | $695K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 5,269 | 4,661 | $618K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.7% | 2,692 | 1,266 | $544K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 2,368 | 1,968 | $536K |
415 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 3,900 | $527K |
| 59025 | Fetal non-stress test | 1.5% | 2,806 | $487K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.4% | 4,311 | $464K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.2% | 1,777 | $387K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.2% | 3,468 | $381K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 1,350 | $309K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,233 | $299K |
| 80053 | Comprehensive metabolic panel | <1% | 35,777 | $239K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 341 | $220K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,795 | $203K |
| 96127 | <1% | 2,150 | $197K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,533 | $195K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,400 | $190K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,212 | $190K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,761 | $186K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,030 | $184K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 700 | $179K |
| 81513 | <1% | 1,177 | $175K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 662 | $169K |
| 76770 | <1% | 929 | $166K | |
| 87631 | <1% | 1,357 | $157K | |
| 96161 | <1% | 1,164 | $157K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,604 | $152K |
| 70498 | <1% | 459 | $127K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 903 | $125K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,024 | $119K |
| 93975 | <1% | 961 | $117K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 686 | $110K |
| 90837 | Psychotherapy session, about an hour | <1% | 742 | $105K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,679 | $101K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 166 | $88K |
| 86850 | <1% | 3,751 | $87K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 141 | $84K |
| 70491 | <1% | 247 | $83K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 499 | $82K |
| 71250 | <1% | 912 | $77K | |
| 0002A | <1% | 2,047 | $77K | |
| 82805 | <1% | 2,304 | $76K | |
| 0001A | <1% | 2,099 | $75K | |
| 92551 | <1% | 1,252 | $75K | |
| 96367 | <1% | 1,167 | $73K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,040 | $73K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 364 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 35,972 | $72K |
| 76642 | <1% | 524 | $67K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 441 | $64K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 183 | $63K |
| 93325 | <1% | 697 | $63K | |
| 97803 | <1% | 752 | $59K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,893 | $58K |
| 36415 | Collection of venous blood by venipuncture | <1% | 52,026 | $56K |
| 93970 | <1% | 446 | $56K | |
| 97161 | <1% | 1,861 | $55K | |
| 76830 | Ultrasound, transvaginal | <1% | 835 | $55K |
| 76536 | <1% | 485 | $53K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,715 | $51K |
| 93971 | <1% | 748 | $50K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 3,496 | $48K |
| 97802 | <1% | 788 | $45K | |
| 72197 | <1% | 150 | $45K | |
| 86900 | <1% | 3,810 | $45K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 371 | $45K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 119 | $45K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 341 | $44K |
| 85027 | <1% | 13,191 | $44K | |
| 93458 | <1% | 37 | $43K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,234 | $42K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,498 | $40K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,919 | $39K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 285 | $39K |
| 77336 | <1% | 322 | $37K | |
| 73610 | <1% | 1,316 | $36K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,520 | $35K |
| 54150 | <1% | 789 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,869 | $32K |
| 97165 | <1% | 843 | $31K | |
| 97116 | <1% | 1,168 | $30K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 421 | $30K |
| 12001 | <1% | 193 | $30K | |
| 86780 | <1% | 1,536 | $29K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,259 | $29K |
| 80061 | Lipid panel | <1% | 2,556 | $28K |
| 94060 | <1% | 288 | $27K | |
| 94010 | <1% | 604 | $27K | |
| 76857 | <1% | 1,043 | $26K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 883 | $25K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 498 | $25K |
| 12011 | <1% | 155 | $24K | |
| 74018 | <1% | 1,130 | $24K | |
| 93799 | <1% | 4,661 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,053 | $22K |
| 87340 | <1% | 1,086 | $22K | |
| 88307 | <1% | 177 | $22K | |
| 74183 | <1% | 100 | $21K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 57 | $20K |
| 96112 | <1% | 72 | $20K | |
| 73502 | <1% | 861 | $20K | |
| 84439 | <1% | 1,483 | $20K | |
| 82728 | <1% | 1,741 | $20K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 597 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,779 | $19K |
| 86803 | <1% | 995 | $19K | |
| 95811 | <1% | 28 | $19K | |
| 20610 | <1% | 149 | $19K | |
| 90688 | <1% | 2,652 | $19K | |
| 84702 | <1% | 1,477 | $19K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 5,175 | $18K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,354 | $18K |
| 73110 | <1% | 891 | $18K | |
| 84484 | <1% | 9,613 | $18K | |
| 83735 | <1% | 11,138 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,213 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,158 | $17K |
| 73030 | <1% | 1,071 | $17K | |
| 86762 | <1% | 486 | $17K | |
| 73630 | <1% | 1,018 | $17K | |
| 86901 | <1% | 3,813 | $17K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 70 | $17K |
| 72100 | <1% | 740 | $16K | |
| 73560 | <1% | 771 | $16K | |
| 82962 | <1% | 11,182 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,076 | $15K |
| 82607 | <1% | 1,111 | $15K | |
| 86140 | <1% | 3,209 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,659 | $15K |
| 73590 | <1% | 684 | $15K | |
| 73564 | <1% | 857 | $15K | |
| 73130 | <1% | 836 | $14K | |
| 70486 | <1% | 461 | $14K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 320 | $14K |
| 80069 | <1% | 1,760 | $14K | |
| 81001 | <1% | 16,388 | $14K | |
| 70496 | <1% | 526 | $13K | |
| 83540 | <1% | 1,908 | $13K | |
| 90715 | <1% | 981 | $13K | |
| 76801 | <1% | 519 | $12K | |
| 90677 | <1% | 884 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,623 | $12K |
| 73700 | <1% | 93 | $12K | |
| 72141 | <1% | 95 | $12K | |
| 0124A | <1% | 400 | $12K | |
| 99152 | <1% | 917 | $11K | |
| 83550 | <1% | 1,887 | $11K | |
| 90670 | <1% | 1,449 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,154 | $10K |
| 90698 | <1% | 1,717 | $10K | |
| 72131 | <1% | 173 | $10K | |
| 85610 | <1% | 4,768 | $10K | |
| 90651 | <1% | 568 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 594 | $9K |
| 0004A | <1% | 244 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 83 | $8K |
| 87481 | <1% | 1,142 | $8K | |
| 62323 | <1% | 48 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 409 | $8K |
| 77300 | <1% | 18 | $8K | |
| A9270 | Non-covered item or service | <1% | 3,068 | $7K |
| 83880 | <1% | 1,575 | $7K | |
| 96368 | <1% | 376 | $7K | |
| 82570 | <1% | 1,314 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,752 | $7K |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 407 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,257 | $7K |
| 96376 | <1% | 3,059 | $6K | |
| 91320 | <1% | 137 | $6K | |
| 90480 | <1% | 392 | $6K | |
| 71271 | <1% | 40 | $6K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 47 | $6K |
| 73552 | <1% | 401 | $6K | |
| 80076 | <1% | 540 | $6K | |
| 90633 | <1% | 915 | $6K | |
| 83655 | <1% | 530 | $5K | |
| 87077 | <1% | 1,583 | $5K | |
| 82950 | <1% | 343 | $5K | |
| 83970 | <1% | 264 | $5K | |
| 83690 | <1% | 5,078 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,384 | $5K |
| 77080 | <1% | 81 | $5K | |
| 0071A | <1% | 170 | $5K | |
| 0072A | <1% | 169 | $5K | |
| 74019 | <1% | 687 | $5K | |
| 84100 | <1% | 1,352 | $4K | |
| 82784 | <1% | 386 | $4K | |
| 0054A | <1% | 340 | $4K | |
| 84153 | <1% | 347 | $4K | |
| 77062 | <1% | 98 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 266 | $4K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 68 | $4K |
| 90680 | <1% | 1,168 | $4K | |
| 76882 | <1% | 41 | $4K | |
| 73080 | <1% | 258 | $4K | |
| 99221 | <1% | 256 | $4K | |
| 73090 | <1% | 415 | $4K | |
| 72170 | <1% | 733 | $4K | |
| 77049 | <1% | 12 | $4K | |
| 87505 | <1% | 33 | $4K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 27 | $4K |
| 99153 | Mod sedat endo service >5yrs | <1% | 434 | $4K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,214 | $4K |
| 10060 | <1% | 22 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,102 | $3K |
| 72040 | <1% | 139 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 120 | $3K |
| 90697 | <1% | 459 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 797 | $3K |
| 82746 | <1% | 536 | $3K | |
| 96158 | <1% | 37 | $3K | |
| 90658 | <1% | 464 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 16 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 698 | $3K |
| 82330 | <1% | 2,604 | $3K | |
| 76870 | <1% | 170 | $3K | |
| 73060 | <1% | 223 | $3K | |
| J3490 | Unclassified drugs | <1% | 285 | $3K |
| 90620 | <1% | 71 | $3K | |
| 96160 | <1% | 16 | $3K | |
| 90744 | <1% | 591 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 131 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 69 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 522 | $3K |
| 72050 | <1% | 43 | $3K | |
| 85018 | <1% | 2,736 | $3K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 77 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,319 | $2K |
| 85652 | <1% | 897 | $2K | |
| 83020 | <1% | 119 | $2K | |
| 99253 | <1% | 68 | $2K | |
| 00840 | <1% | 380 | $2K | |
| 90461 | <1% | 1,671 | $2K | |
| 0003A | <1% | 56 | $2K | |
| 84156 | <1% | 853 | $2K | |
| 85730 | <1% | 1,956 | $2K | |
| 83605 | <1% | 3,576 | $2K | |
| 86923 | <1% | 90 | $2K | |
| 87186 | <1% | 1,128 | $2K | |
| 90716 | <1% | 332 | $2K | |
| 82550 | <1% | 1,258 | $2K | |
| 90619 | <1% | 278 | $2K | |
| 82077 | <1% | 1,901 | $2K | |
| 94729 | <1% | 57 | $2K | |
| 82947 | <1% | 2,389 | $2K | |
| 82533 | <1% | 197 | $2K | |
| 82043 | <1% | 387 | $2K | |
| 86870 | <1% | 38 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 71 | $2K |
| 77061 | <1% | 45 | $2K | |
| 87070 | <1% | 577 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 51 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 184 | $2K |
| 86706 | <1% | 131 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 637 | $2K |
| 83615 | <1% | 559 | $2K | |
| 90707 | <1% | 405 | $2K | |
| 84403 | <1% | 102 | $2K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 362 | $1K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 72 | $1K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 13 | $1K |
| J1815 | Injection, insulin, per 5 units | <1% | 131 | $1K |
| 76825 | <1% | 12 | $1K | |
| 88341 | <1% | 16 | $1K | |
| 90696 | <1% | 195 | $1K | |
| 87040 | <1% | 1,407 | $1K | |
| 85379 | <1% | 1,268 | $1K | |
| 84550 | <1% | 344 | $1K | |
| 80197 | <1% | 75 | $1K | |
| 82565 | <1% | 119 | $1K | |
| 81003 | <1% | 2,734 | $1K | |
| 86364 | <1% | 102 | $1K | |
| 85041 | <1% | 162 | $1K | |
| 81025 | <1% | 5,860 | $1K | |
| 87493 | <1% | 47 | $1K | |
| 84132 | <1% | 2,743 | $1K | |
| 0052A | <1% | 70 | $1K | |
| 82435 | <1% | 2,134 | $1K | |
| 82375 | <1% | 2,312 | $1K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 25 | $963.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,314 | $930.50 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 83 | $904.36 |
| S9443 | Lactation classes, non-physician provider, per session | <1% | 17 | $886.17 |
| 83001 | <1% | 32 | $881.40 | |
| 85045 | <1% | 393 | $866.95 | |
| 82248 | <1% | 253 | $862.99 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,421 | $848.19 |
| 95012 | <1% | 16 | $813.78 | |
| 97162 | <1% | 16 | $801.34 | |
| 86038 | <1% | 48 | $777.19 | |
| 00731 | <1% | 224 | $761.72 | |
| 84145 | <1% | 229 | $752.32 | |
| 87205 | <1% | 558 | $739.50 | |
| 72110 | <1% | 19 | $732.56 | |
| 87522 | Neg quan hep c or qual rna | <1% | 32 | $709.02 |
| 86308 | <1% | 354 | $692.67 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 97 | $690.81 |
| 84703 | <1% | 627 | $688.33 | |
| 73140 | <1% | 144 | $673.65 | |
| 83050 | <1% | 2,324 | $664.23 | |
| 76827 | <1% | 12 | $662.63 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,795 | $651.53 |
| 90710 | <1% | 178 | $633.85 | |
| 88304 | <1% | 328 | $630.12 | |
| 99243 | <1% | 26 | $591.05 | |
| 90686 | <1% | 75 | $589.54 | |
| 84295 | <1% | 2,271 | $582.78 | |
| 0051A | <1% | 41 | $574.30 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,547 | $558.82 |
| 90662 | <1% | 77 | $551.98 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 18 | $538.92 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,235 | $524.22 |
| 87653 | <1% | 51 | $499.03 | |
| 99349 | <1% | 17 | $479.02 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 37 | $475.96 |
| 0154A | <1% | 14 | $462.84 | |
| 72072 | <1% | 30 | $449.25 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 456 | $444.79 |
| 93320 | <1% | 185 | $432.24 | |
| 86258 | <1% | 18 | $422.67 | |
| 73000 | <1% | 20 | $419.93 | |
| 0064A | <1% | 19 | $419.02 | |
| 86703 | <1% | 289 | $413.45 | |
| 84146 | <1% | 16 | $395.42 | |
| 84481 | <1% | 56 | $389.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,802 | $357.84 |
| 51798 | <1% | 112 | $355.07 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,183 | $352.44 |
| 84460 | <1% | 70 | $344.05 | |
| 86480 | <1% | 14 | $328.75 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,511 | $325.28 |
| 84450 | <1% | 55 | $319.88 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 15 | $292.65 |
| 87486 | <1% | 68 | $273.93 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,745 | $252.45 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14 | $251.77 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 396 | $248.31 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,496 | $230.07 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 223 | $220.87 |
| 83921 | <1% | 15 | $216.81 | |
| 73070 | <1% | 14 | $213.28 | |
| 86003 | <1% | 13 | $201.21 | |
| 87581 | <1% | 68 | $193.73 | |
| 86304 | <1% | 15 | $189.19 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $186.56 |
| 77091 | <1% | 15 | $181.52 | |
| 82150 | <1% | 81 | $180.06 | |
| 88342 | <1% | 100 | $178.77 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,342 | $170.88 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 509 | $166.63 |
| 80143 | <1% | 159 | $154.73 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,918 | $150.04 |
| 82247 | <1% | 46 | $133.25 | |
| C1769 | Guide wire | <1% | 843 | $126.94 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,792 | $113.61 |
| 80179 | <1% | 120 | $107.03 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 799 | $102.23 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,774 | $100.70 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 696 | $97.58 |
| 85384 | <1% | 46 | $92.60 | |
| C2625 | Stent, non-coronary, temporary, with delivery system | <1% | 32 | $87.88 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,084 | $86.77 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 424 | $86.45 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 663 | $77.15 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 316 | $74.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,981 | $73.40 |
| 82378 | <1% | 13 | $71.18 | |
| 82010 | <1% | 154 | $69.48 | |
| 90685 | <1% | 12 | $66.50 | |
| 90474 | <1% | 145 | $63.82 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 109 | $61.91 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 904 | $59.05 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,844 | $58.95 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 393 | $58.41 |
| 81002 | <1% | 62 | $57.68 | |
| 91300 | <1% | 4,472 | $56.37 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14 | $56.25 |
| 87088 | <1% | 47 | $55.59 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,076 | $52.96 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 689 | $48.50 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 354 | $43.01 |
| 87430 | <1% | 17 | $36.83 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 403 | $33.44 |
| 82803 | <1% | 38 | $32.80 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 711 | $32.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 104 | $21.44 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 52 | $20.78 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,918 | $18.91 |
| 88720 | <1% | 270 | $9.97 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 419 | $9.67 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 445 | $8.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 296 | $7.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 95 | $4.40 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 80 | $3.66 |
| 91307 | <1% | 411 | $2.81 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 587 | $2.00 |
| 91305 | <1% | 450 | $1.73 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 188 | $1.61 |
| 91312 | <1% | 303 | $1.42 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 40 | $1.05 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,273 | $0.65 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 43 | $0.46 |
| 91308 | <1% | 47 | $0.39 | |
| 91315 | <1% | 14 | $0.12 | |
| 91306 | <1% | 19 | $0.11 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 1,503 | $0.00 |
| 96417 | 0% | 282 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 386 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 89 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 70 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 809 | $0.00 |
| 76377 | 0% | 120 | $0.00 | |
| 94760 | 0% | 2,102 | $0.00 | |
| 00142 | 0% | 168 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 34 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 62 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 14 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.